Lead Product(s) : CD-001
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CD (Suzhou) Biopharma Announces FDA Clearance for Phase I Clinical Trial of CD-001
Details : CD-001 is built on its BsFP platform. This potential therapy, designed to target PD-1 positive CD8+ T cells, aims to address unmet medical needs in oncology and viral infections.
Product Name : CD-001
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
September 20, 2024
Lead Product(s) : CD-001
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable